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With interest we read the article by Esposito et al. about
a female child with myopathy and left ventricular hyper-
trabeculation / noncompaction (LVHT) carrying a muta-
tion in two different genes, the integrin-α7 gene and the
myosin heavy chain 7B gene (MYH7B) [1]. We have the
following comments and concerns.
The authors mention in the discussion that MYL2 and
MYL3 mutations were found in patients with LVHT [1].
Among the 5 papers cited to corroborate this statement
Budde et al. [2] did not look for MYL2 or MYL3 muta-
tions and Klaassen et al. [3] and Probst et al. [4] defini-
tively state that no mutations in MYL2 or MYL3 were
found. Hoedemaekers et al. 2010 [5] tested for MYL2
and MYL3 but do not mention a mutation in these
genes in their results either. Walsh et al. 2010 [6] is not
an original paper but a review about MYH7 mutations.
LVHT has not only been found in association with mu-
tations in the TAZ, DTNA, ZASP, lamin A/C, MYH7,
ACTC1, TNNT2, TNNI3, MYBPC3, and TPM1 genes but
also in association with mutations in the dystrophin,
DMPK, ZNF9, LAMP2, GAA, mtDNA, AMPD1, GBE1,
RYR1, COL7A1, PMP22, MMACHC, beta-globin, and
DNAJC19 genes [Finsterer et al., submitted].
The index patient underwent echocardiography at age
1 month but LVHT was diagnosed not before the next
echocardiographic examination at age 17 months. Which
is the reason why LVHT was not detected at the initial
examination? Was LVHT missed because of poor image
quality, absent awareness of the pathology, ignoring the
abnormality, left ventricular hypertrophy at the initial in-
vestigation, severe dilation of the left ventricle, or did
LVHT truly develop during the period between the two
examinations (acquired LVHT)? Did the authors review
the initial echocardiographic examination? Did the pres-
ence of a patent arterial duct and patent foramen ovale
prevent LVHT from being diagnosed at the initial
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may be detected or suspected only upon creatine-kinase
(CK) screening, needle electromyography or muscle bi-
opsy at this stage [7]. Were the three other females with
LVHT or other family members seen by a myologist?
Did they report any symptoms indicative of a muscle
disease? Were any signs found which suggested the pres-
ence of a neuromuscular disorder? Which were the CK
values in these three individuals? Since all family mem-
bers underwent needle electromyography and muscle
biopsy it would be worthwhile to know if these investi-
gations were abnormal in any of them as well.
The patient obviously died from sudden cardiac death,
which is a frequent complication in patients with LVHT.
Were there any other family members of the 5 gener-
ation family in whom sudden cardiac death has been re-
ported? Since ECGs had been recorded in all family
members it would be interesting to know if QTc was
prolonged in any member other than the index patient?
Was implantation of an implantable cardioverter defib-
rillator ever considered in case V/4?
Since LVHT may be also complicated by cardioem-
bolic events, death could be attributable also to fatal
cerebral or cardiac embolism [8]. Did the patient
undergo autopsy including the cerebrum to exclude such
a cause?
The authors mention that the index patient underwent
cardiac MRI at age 10y. Was any late enhancement ob-
served and if there was late enhancement how was it
distributed?
Overall, the interesting paper by Esposito et al. evokes
a number of questions, which require further discussion.
Currently, there is no proof that LVHT is causally linked
to any of the mutations so far described in association
with LVHT.
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